Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma

Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma - Lenvatinib-induced thyroid abnormalities in unresectable hepatocellular carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036397

Enrollment

Registered

2019-04-03

Start date

2019-02-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who received lenvatinib treatment for unresectable hepatocellular carcinoma.

Exclusion criteria

Exclusion criteria: There are no exclusion criteria as they are for diagnosed patients.

Design outcomes

Primary

Measure	Time frame
Collect and evaluate data on thyroid function changes, duration of treatment, treatment effects, turning points, causes of death.	—

Secondary

Measure	Time frame
1) General clinical examination: Collect data at the time of diagnosis, regular visit, and the end of treatment for treatment. 2) Collect data on age, gender, treatment start date, Child-Pugh classification, and complications.	—

Countries

Japan

Contacts

Public ContactYohei Koizumi

Ehime University Graduate School of Medicine Departments of Gastroenterology and Metabology

ykoizumi@m.ehime-u.ac.jp089-960-5308

Outcome results